Literature DB >> 18376195

Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.

Karl Y Bilimoria1, Mark S Talamonti, James S Tomlinson, Andrew K Stewart, David P Winchester, Clifford Y Ko, David J Bentrem.   

Abstract

BACKGROUND: Pancreatic neuroendocrine tumors (PNET) have a poorly defined natural history, and a staging system is not available. The objective of this study was to identify factors predicting survival after pancreatectomy for PNETs and to establish a postresection prognostic score. PATIENTS AND METHODS: From the National Cancer Data Base (1985-2004), patients were identified who underwent PNET resection. Multivariable Cox proportional hazards modeling was used to assess the impact of patient, tumor, treatment, and hospital factors on survival. A prognostic score based on the predictive factors from the Cox model was developed.
RESULTS: Three thousand eight hundred fifty-one patients underwent resection for PNETs. Five-year overall survival was 59.3%, and the 10-year survival was 37.7%. On multivariable analysis, age, grade, distant metastases, tumor functionality, and type of resection were independent predictors of survival after resection of PNETs (P < 0.0001). Gender, race, socioeconomic status, tumor size, nodal status, margins, adjuvant chemotherapy, and hospital volume were not associated with survival. Age, grade, and distant metastases were the most significant predictors of survival and were incorporated into a PNET postresection prognostic score. The prognostic score correlated with outcomes and offered excellent survival discrimination by each of the 3 score subgroups: 76.7%, 50.9%, and 35.7% (P < 0.0001). The concordance index was 0.63 (95% CI 0.59-0.67), indicating reasonable agreement between actual outcomes and that predicted by the prognostic score.
CONCLUSIONS: The prognostic score can be used to predict outcomes, guide adjuvant treatment, and stratify patients for clinical trials.

Entities:  

Mesh:

Year:  2008        PMID: 18376195     DOI: 10.1097/SLA.0b013e31815b9cae

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  116 in total

1.  T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases.

Authors:  Steven C Katz; Charan Donkor; Kristen Glasgow; Venu G Pillarisetty; Mithat Gönen; N Joseph Espat; David S Klimstra; Michael I D'Angelica; Peter J Allen; William Jarnagin; Ronald P Dematteo; Murray F Brennan; Laura H Tang
Journal:  HPB (Oxford)       Date:  2010-12       Impact factor: 3.647

2.  miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts.

Authors:  Hanno Matthaei; Dennis Wylie; Maura B Lloyd; Marco Dal Molin; Jon Kemppainen; Skye C Mayo; Christopher L Wolfgang; Richard D Schulick; Laura Langfield; Bernard F Andruss; Alex T Adai; Ralph H Hruban; Anna E Szafranska-Schwarzbach; Anirban Maitra
Journal:  Clin Cancer Res       Date:  2012-06-21       Impact factor: 12.531

3.  Pancreatic neuroendocrine tumours: hypoenhancement on arterial phase computed tomography predicts biological aggressiveness.

Authors:  David J Worhunsky; Geoffrey W Krampitz; Peter D Poullos; Brendan C Visser; Pamela L Kunz; George A Fisher; Jeffrey A Norton; George A Poultsides
Journal:  HPB (Oxford)       Date:  2013-08-29       Impact factor: 3.647

4.  Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors.

Authors:  Susan M Sharpe; Haejin In; David J Winchester; Mark S Talamonti; Marshall S Baker
Journal:  J Gastrointest Surg       Date:  2014-08-26       Impact factor: 3.452

5.  Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes.

Authors:  Christina L Roland; Aihua Bian; John C Mansour; Adam C Yopp; Glen C Balch; Rohit Sharma; Xian-Jin Xie; Roderich E Schwarz
Journal:  J Surg Oncol       Date:  2011-10-17       Impact factor: 3.454

6.  Pre-operative Sarcopenia Identifies Patients at Risk for Poor Survival After Resection of Biliary Tract Cancers.

Authors:  Jeffery Chakedis; Gaya Spolverato; Eliza W Beal; Ingrid Woelfel; Fabio Bagante; Katiuscha Merath; Steven H Sun; Aaron Chafitz; Jason Galo; Mary Dillhoff; Jordan Cloyd; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2018-05-31       Impact factor: 3.452

7.  Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.

Authors:  Joo Young Kim; Jacqueline A Brosnan-Cashman; Soyeon An; Sung Joo Kim; Ki-Byung Song; Min-Sun Kim; Mi-Ju Kim; Dae Wook Hwang; Alan K Meeker; Eunsil Yu; Song Cheol Kim; Ralph H Hruban; Christopher M Heaphy; Seung-Mo Hong
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

8.  Increased rate of clinically relevant pancreatic fistula after deep enucleation of small pancreatic tumors.

Authors:  Kristin Heeger; Massimo Falconi; Stefano Partelli; Jens Waldmann; Stefano Crippa; Volker Fendrich; Detlef K Bartsch
Journal:  Langenbecks Arch Surg       Date:  2014-02-14       Impact factor: 3.445

Review 9.  [Complications of minimally invasive pancreas resection for pancreatic neuroendocrine tumors].

Authors:  U A Wittel; U T Hopt
Journal:  Chirurg       Date:  2015-01       Impact factor: 0.955

10.  [Total pancreatectomy: renaissance of a surgical procedure].

Authors:  T Keck; U T Hopt
Journal:  Chirurg       Date:  2008-12       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.